Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska

  • Bruce M
  • Singleton R
  • Bulkow L
 et al. 
  • 39

    Readers

    Mendeley users who have this article in their library.
  • 18

    Citations

    Citations of this article.

Abstract

Background: Alaska Native (AN) children have experienced high rates of invasive pneumococcal disease (IPD). In March 2010, PCV13 was introduced statewide in Alaska. We evaluated the impact of PCV13 on IPD in children and adults, 45 months after introduction. Methods: Pneumococcal sterile site isolates, reported through state-wide surveillance, were serotyped using standard methods. We defined a pre-PCV13 time period 2005-2008 and post-PCV13 time period April 2010-December 2013; excluding Jan 2009-March 2010 because PCV13 was introduced pre-licensure in one high-risk region in 2009. Results: Among Alaska children

Author-supplied keywords

  • Alaska
  • Carriage
  • Invasive pneumococcal disease
  • Serotype
  • Streptococcus pneumoniae
  • US
  • Vaccine

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • Michael G. Bruce

  • Rosalyn Singleton

  • Lisa Bulkow

  • Karen Rudolph

  • Tammy Zulz

  • Prabhu Gounder

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free